GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (FRA:ANW) » Definitions » Gross-Profit-to-Asset %

Immuron (FRA:ANW) Gross-Profit-to-Asset % : 15.02% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Immuron Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Immuron's annualized Gross Profit for the quarter that ended in Dec. 2023 was €1.94 Mil. Immuron's average Total Assets over the quarter that ended in Dec. 2023 was €12.91 Mil. Therefore, Immuron's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 15.02%.


Immuron Gross-Profit-to-Asset % Historical Data

The historical data trend for Immuron's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Gross-Profit-to-Asset % Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only 18.89 24.74 0.57 2.07 5.38

Immuron Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.24 2.96 3.50 7.71 15.02

Competitive Comparison of Immuron's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Immuron's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immuron's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuron's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Immuron's Gross-Profit-to-Asset % falls into.



Immuron Gross-Profit-to-Asset % Calculation

Immuron's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Jun. 2023 )/( (Total Assets (A: Jun. 2022 )+Total Assets (A: Jun. 2023 ))/ count )
=0.811/( (16.524+13.621)/ 2 )
=0.811/15.0725
=5.38 %

Immuron's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=1.94/( (13.621+12.204)/ 2 )
=1.94/12.9125
=15.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Immuron Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Immuron's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuron (FRA:ANW) Business Description

Traded in Other Exchanges
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (FRA:ANW) Headlines

No Headlines